RT Journal Article SR Electronic T1 A Randomised Crossover Trial: Exploring the Dose-Response effect Of Carbohydrate restriction on glycaemia in people with type 2 diabetes (D-ROC2) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.30.21258049 DO 10.1101/2021.05.30.21258049 A1 Ebaa Al Ozairi A1 Muhammad Abdul-Ghani A1 Nick Oliver A1 Brandon Whitcher A1 Reem Al Awadi A1 Abeer El Samad A1 Etab Taghadom A1 Jumana Al-Kandari A1 Nicola Guess YR 2021 UL http://medrxiv.org/content/early/2021/06/01/2021.05.30.21258049.abstract AB Aims The role of carbohydrate restriction in the management of glycaemia in type 2 diabetes (T2D) has been a subject of immense debate and controversy partly due to low-carbohydrate trials being confounded by multiple factors including degree of calorie restriction, dietary protein content, and by no clear definition of a low-carbohydrate diet. The current study sought to provide insight into the relationship between carbohydrate restriction and glycaemia by testing the effect of varying doses of carbohydrate on continuous glucose concentrations within a range of intakes defined as low-carbohydrate while controlling for confounding factors.Methods This was a randomised crossover trial in participants with T2D testing 5 different 6-day eucaloric, isocaloric dietary treatments with varying carbohydrate contents (10%, 15%, 20%, 25%, and 30% kcal). Diets were kept isocaloric by exchanging %kcal from carbohydrate with predominantly unsaturated fat, keeping protein constant at 15% kcal. Daily self-weighing was employed to ensure participants maintained their weight throughout each treatment arm. Between dietary treatments, participants underwent a washout period of at least 7 days and were advised to maintain their habitual diet. Glycemic control was assessed using a continuous glucose monitoring device that was placed while the participant was on their normal diet, and was worn for the 6 days of each treatment.Results 12 participants completed the study. There were no differences in 24-hour and postprandial sensor glucose concentrations between the 30%kcal and 10%kcal doses (7.4 ± 1.1mmol/L vs 7.6 ± 1.4mmol/L (P=0.28) and 8.0 ± 1.4mmol/L vs 8.3 ± 1.3mmol/L (P=0.28) respectively). In our exploratory analyses we did not find any dose-response relationship between carbohydrate intake and glycaemia. A small amount of weight loss occurred in each treatment arm (range: 0.4 to 1.1kg over the 6 days) but adjusting for these differences did not influence the primary or secondary outcomes.Conclusions Modest changes in dietary carbohydrate content in the absence of weight loss while keeping dietary protein intake constant do not appear to influence glucose concentrations in people with T2D.Trial Registration ISRCTN 11067343.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTrial Registration: ISRCTN 11067343Funding StatementThis study was funded by the Kuwaiti Foundation for the Advancement of Science. The funder had no role in the design of the study, data collection, analysis, manuscript preparation or publication decisions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Dasman Diabetes Institute Research Ethics Committee (ref: RA HM-2018-04) and prospectively registered with the International Standard Randomised Controlled Trial Number (11067343). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets during and/or analysed during the current study available from the corresponding author on reasonable request.CGMcontinuous glucose monitoringCONGAcontinuous overlapping net glycemic actionHBGIhigh blood glucose indexLBGIlow blood glucose indexMAGEmean amplitude glucose excursionsPALphysical activity levelT2Dtype 2 diabetes.